Please login to the form below

Not currently logged in
Email:
Password:

Amgen and Boehringer drugs win FDA breakthrough status

Leukaemia drug and Pradaxa antidote will benefit from accelerated regulatory processes
FDA headquarters White Oak

The US FDA's run of 'breakthrough' designations for innovative new products continues with newly-awarded expedited reviews for medicines from Amgen and Boehringer Ingelheim.

Amgen received the designation for its cancer antibody blinatumomab for use in the treatment of adults with a specific form of acute lymphoblastic leukaemia (ALL), while Boehringer's is for an antidote to its anticoagulant Pradaxa (dabigatran etexilate).

The FDA introduced its breakthrough status designation in 2012 to speed up the review process for important new drugs in serious or life threatening conditions that have shown substantial improvements over existing options during clinical trials.

Blinatumomab qualifies as it has demonstrated positive results in Philadelphia-negative (Ph-) relapsed/refractory B-precursor ALL – a cancer of the blood and bone marrow for which there are few treatment options.

The drug is part a new class of immunotherapy called bi-specific T cell engagers or BiTE antibodies, which direct T cells to kill cancer cells.

Boehringer's breakthrough status is for idarucizumab, which acts as an antidote to its blood clot treatment Pradaxa.

Pradaxa is one of several important new oral anticoagulants to hit the market in recent years that can provide more convenient alternatives to traditional treatments warfarin and heparin.

However, unlike these older therapies, there are no antidotes to reverse their effects when patients develop severe bleeds.

Boehringer is developing idarucizumab to address this issue, potentially giving it the edge over its rivals - such as Bayer/Janssen's Xarelto (rivaroxaban) and Bristol-Myers Squibb/Pfizer's Eliquis (apixaban).

The drug has already shown its effect in early trials and is now being studied in the global REVERSE-AD study to test its use in the clinical setting in patients taking Pradaxa.

Article by
Thomas Meek

2nd July 2014

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Dovetail

We're award-winning joint working specialists. We help our clients to transform healthcare through effective collaboration, and deliver work to feel...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics